drugset / Trial / NCT06341647
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
Timeline
- Start
- 2024-10-31
- Primary completion
- 2027-04
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANPOCOGIN | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |